RGS16 overexpression in breast cancer cells inhibits the cell prolife ration dependent on epidermal growth factor (EGF), and decreased RGS16 expression was associated with a reduction in the cell proliferation rate and an increased resistance to tyrosine kinase inhibitors. Here, RGS16 is linked to breast cancer.